Zobrazeno 1 - 3
of 3
pro vyhledávání: '"A. M. Abdelgafur"'
Autor:
Lylee Norah M. AbdelGafur
Publikováno v:
International Journal of Linguistics, Literature and Translation. 3:23-30
Pronunciation is a key element of the learning of oral skills in a second language. The role it plays in an English language program varies and the amount of time and effort devoted to it seems to depend to a large degree on the linguistic models and
Autor:
M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, E. V. Lymar, E. G. Ovchinnikova, T. A. Sveklina, E. A. Usynin, A. M. Abdelgafur, E. A. Tararova, L. M. Shumova, A. S. Belenkov, I. Yu. Dolgov, N. G. Ponomareva, I. V. Evstigneeva, A. N. Ivanov, A. R. Isaev, R. V. Leonenkov, A. V. Meskikh, M. R. Mukhitova, S. A. Orlova, I. V. Teslenok, M. M. Shegurova, M. T. Aivazov, Z. V. Amoev, K. G. Babina, A. A. Vorontsova, E. V. Karabina, N. V. Kirdakova, I. E. Shumskaya, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, E. S. Lyutova, M. M. Fael, A. N Chugarova, A. S. Antipin
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 31-44 (2021)
Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutiv
Autor:
M. I. Volkova, A. M. Abdelgafur, M. T. Aivazov, Z. V. Amoev, K. G. Babina, P. S. Borisov, A. A. Vorontsovа, I. V. Evstigneeva, O. I. Evsyukova, O. V. Zhelezin, A. S. Kalpinsky, E. V. Karabina, N. V. Kirdakova, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, R. V. Leonenkov, M. R. Maturov, A. V. Meskikh, S. V. Mishugin, E. G. Ovchinnikova, A. S. Olshanskaya, S. A. Protsenko, T. Yu. Semiglazova, R. V. Smirnov, E. A. Usynin, M. M. Fael, E. M. Cherniakova, I. E. Shumskaya
Publikováno v:
Onkourologiâ, Vol 15, Iss 3, Pp 56-69 (2019)
Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russ